Urofollitropin
Bravelle (urofollitropin) is an unknown pharmaceutical. Urofollitropin was first approved as Bravelle on 2002-05-06. It is used to treat female infertility and polycystic ovary syndrome in the USA. The pharmaceutical is active against follicle-stimulating hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Urofollitropin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Bravelle | urofollitropin | Ferring Pharmaceuticals | N-21289 DISCN | 2002-05-06 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| polycystic ovary syndrome | EFO_0000660 | D011085 | E28.2 |
| female infertility | EFO_0008560 | D007247 | N97 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3355 | Injection, urofollitropin, 75 iu |
Clinical
Clinical Trials
151 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | HP_0000789 | — | 10 | 11 | 29 | 27 | 20 | 96 |
| Female infertility | D007247 | EFO_0008560 | N97 | 5 | 2 | 6 | 3 | 5 | 20 |
| Ovulation induction | D010062 | — | — | 1 | 6 | 3 | 1 | 2 | 13 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | 5 | 3 | 3 | 12 |
| Fertilization in vitro | D005307 | — | — | — | — | 1 | 5 | 4 | 10 |
| Syndrome | D013577 | — | — | — | 1 | 2 | 3 | 3 | 9 |
| Hypogonadism | D007006 | HP_0000044 | E23.0 | — | 1 | 2 | 4 | 2 | 9 |
| Anovulation | D000858 | — | — | — | — | 4 | 1 | 1 | 6 |
| Intracytoplasmic sperm injections | D020554 | — | — | — | — | — | 4 | 1 | 5 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | 1 | 1 | 3 | — | 5 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Azoospermia | D053713 | EFO_0000279 | N46.0 | — | 1 | 1 | — | 1 | 3 |
| Assisted reproductive techniques | D027724 | — | — | — | — | 2 | — | 1 | 3 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | — | 1 | — | 1 | 2 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 2 | — | — | 2 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | — | 1 | — | 1 | 2 |
| Embryo transfer | D004624 | — | — | — | — | 1 | — | — | 1 |
| Oligospermia | D009845 | — | N46.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | — | — | 2 | 3 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 5 | 5 |
| In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 2 | 2 |
| Ovarian pregnancy | D065172 | — | O00.2 | — | — | — | — | 1 | 1 |
| Fertility | D005298 | — | — | — | — | — | — | 1 | 1 |
| Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
| Embryo culture techniques | D046149 | — | — | — | — | — | — | 1 | 1 |
| Aneuploidy | D000782 | — | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Acupuncture therapy | D015670 | — | — | — | — | — | — | 1 | 1 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Urofollitropin |
| INN | urofollitropin |
| Description | Follitropin beta chain precursor (Follicle-stimulating hormone beta subunit) (FSH-beta) |
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201520 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00094 |
| UNII ID | W9BB98U6HP (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Urofollitropin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 582 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
271 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use